Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4
| Autor: | Illouz, Frédéric, Wang, Daniel Y, Ye, Fei, Zhao, Shilin, Johnson, Douglas B, Gupta, A., De Felice, K. M., Loftus, E. V., Khanna, S., Beck, Kimberly E., Blansfield, Joseph A., Tran, Khoi Q., Feldman, Andrew L., Hughes, Marybeth S., Royal, Richard E., Kammula, Udai S., Topalian, Suzanne L., Sherry, Richard M., Kleiner, David, Quezado, Martha, Lowy, Israel, Yellin, Michael, Rosenberg, Steven A., Yang, James C., Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, Franck, Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., Massard, C., Fuerea, A., Ribrag, V., Gazzah, A., Armand, J. P., Amellal, N., Angevin, E., Noel, N., Boutros, C., Mateus, C., Robert, C., Soria, J. C., Marabelle, A., Lambotte, O., Gonzalez, Raul S., Salaria, Safia N., Bohannon, Caitlin D., Huber, Aaron R., Feely, Michael M., Shi, Chanjuan, Marthey, L., Mussini, C., Nachury, M., Nancey, S., Grange, F., Zallot, C., Peyrin-Biroulet, L., Rahier, J. F., de Beauregard, M. Bourdier, Mortier, L., Coutzac, C., Soularue, E., Lanoy, E., Kapel, N., Planchard, D., Chaput, N., Benson, Al B., Ajani, Jaffer A., Catalano, Robert B., Engelking, Constance, Kornblau, Steven M., Martenson, James A., McCallum, Richard, Mitchell, Edith P., O'Dorisio, Thomas M., Vokes, Everett E., Wadler, Scott, Haanen, J B A G, Kerr, K M, Peters, S, Larkin, J, Jordan, K, Bergqvist, Viktoria, Hertervig, Erik, Gedeon, Peter, Kopljar, Marija, Griph, Håkan, Kinhult, Sara, Carneiro, Ana, Marsal, Jan, Hsieh, Amy Hsin Chieh, Ferman, Mutaz, Brown, Michael P., Andrews, Jane M., Trainer, Harris, Hulse, Paul, Higham, Claire E, Trainer, Peter, Lorigan, Paul, Hughes, Jing, Vudattu, Nalini, Sznol, Mario, Gettinger, Scott, Kluger, Harriet, Lupsa, Beatrice, Herold, Kevan C |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
Skin Neoplasms Cytotoxic medicine.medical_treatment Autoimmunity Dermatitis Lymphocyte Activation Gastroenterology Immune-related adverse events T-Lymphocyte Subsets Adrenal Cortex Hormones 80 and over Immune-checkpoint inhibitor induced enterocolitis Neoplasm Metastasis Melanoma Enterocolitis Membrane Glycoproteins Subcutaneous Vaccination Antibodies Monoclonal programmed cell death protein 1 Kidney Neoplasms Neoplasm Proteins Oncology Disease Progression chemically induced Lung cancer Nivolumab gastroenteritis Type 1 medicine.medical_specialty Antineoplastic Agents chemistry Antigen Antigens CD HLA-A2 Antigen Diabetes Mellitus Humans Tumour neoantigen Aged ResearchInstitutes_Networks_Beacons/mcrc Immunotherapy medicine.disease Peptide Fragments Immunology adverse effects gastrointestinal tract Peptides Immune checkpoint blockade Autoimmune Cancer Research colitis T-Lymphocytes Programmed Cell Death 1 Receptor administration & dosage Anti-CTLA-4 Hepatitis immunology Neoplasms Monoclonal CTLA-4 Antigen Manchester Cancer Research Centre Anti-PD-1 antibody Cytotoxic T-lymphocyte-associated antigen 4 Middle Aged CD Differentiation Female immunotherapy medicine.symptom Intravenous gp100 Melanoma Antigen medicine.drug Adult etiology Vitiligo chemical and pharmacologic phenomena Ipilimumab Cancer Vaccines Antibodies Autoimmune Diseases Injections Gastrointestinal Agents blood Internal medicine Immune Tolerance medicine Antigens Vedolizumab treatment against irAEs Carcinoma Renal Cell Salvage Therapy therapy business.industry Cancer Antigens Differentiation Infliximab therapeutic use physiology Neoplasm pathology business |
| Zdroj: | Illouz, F, Wang, D Y, Ye, F, Zhao, S, Johnson, D B, Gupta, A, De Felice, K M, Loftus, E V, Khanna, S, Beck, K E, Blansfield, J A, Tran, K Q, Feldman, A L, Hughes, M S, Royal, R E, Kammula, U S, Topalian, S L, Sherry, R M, Kleiner, D, Quezado, M, Lowy, I, Yellin, M, Rosenberg, S A, Yang, J C, Michot, J M, Bigenwald, C, Champiat, S, Collins, M, Carbonnel, F, Postel-Vinay, S, Berdelou, A, Varga, A, Bahleda, R, Hollebecque, A, Massard, C, Fuerea, A, Ribrag, V, Gazzah, A, Armand, J P, Amellal, N, Angevin, E, Noel, N, Boutros, C, Mateus, C, Robert, C, Soria, J C, Marabelle, A, Lambotte, O, Gonzalez, R S, Salaria, S N, Bohannon, C D, Huber, A R, Feely, M M, Shi, C, Marthey, L, Mateus, C, Mussini, C, Nachury, M, Nancey, S, Grange, F, Zallot, C, Peyrin-Biroulet, L, Rahier, J F, de Beauregard, M B, Mortier, L, Coutzac, C, Soularue, E, Lanoy, E, Kapel, N, Planchard, D, Chaput, N, Robert, C, Carbonnel, F, Benson, A B, Ajani, J A, Catalano, R B, Engelking, C, Kornblau, S M, Martenson, J A, McCallum, R, Mitchell, E P, O'Dorisio, T M, Vokes, E E, Wadler, S, Haanen, J B A G, Carbonnel, F, Robert, C, Kerr, K M, Peters, S, Larkin, J, Jordan, K, Bergqvist, V, Hertervig, E, Gedeon, P, Kopljar, M, Griph, H, Kinhult, S, Carneiro, A, Marsal, J, Hsieh, A H C, Ferman, M, Brown, M P, Andrews, J M, Trainer, H, Hulse, P, Higham, C E, Trainer, P, Lorigan, P, Hughes, J, Vudattu, N, Sznol, M, Gettinger, S, Kluger, H, Lupsa, B & Herold, K C 2006, ' Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 ', Journal of Clinical Oncology, pp. 2283-2289 . https://doi.org/10.1200/JCO.2005.04.5716 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | PurposeCytotoxic T-lymphocyte–associated antigen 4 (CTLA4) is an inhibitory receptor on T cells. Knocking out CTLA4 in mice causes lethal lymphoproliferation, and polymorphisms in human CTLA4 are associated with autoimmune disease. Trials of the anti-CTLA4 antibody ipilimumab (MDX-010) have resulted in durable cancer regression and immune-mediated toxicities. A report on the diagnosis, pathology, treatment, clinical outcome, and significance of the immune-mediated enterocolitis seen with ipilimumab is presented.Patients and MethodsWe treated 198 patients with metastatic melanoma (MM) or renal cell carcinoma (RCC) with ipilimumab.ResultsThe overall objective tumor response rate was 14%. We observed several immune mediated toxicities including dermatitis, enterocolitis, hypophysitis, uveitis, hepatitis, and nephritis. Enterocolitis, defined by grade 3/4 clinical presentation and/or biopsy documentation, was the most common major toxicity (21% of patients). It presented with diarrhea, and biopsies showed both neutrophilic and lymphocytic inflammation. Most patients who developed enterocolitis responded to high-dose systemic corticosteroids. There was no evidence that steroid administration affected tumor responses. Five patients developed perforation or required colectomy. Four other patients with steroid-refractory enterocolitis appeared to respond promptly to tumor necrosis factor alpha blockade with infliximab. Objective tumor response rates in patients with enterocolitis were 36% for MM and 35% for RCC, compared with 11% and 2% in patients without enterocolitis, respectively (P = .0065 for MM and P = .0016 for RCC).ConclusionCTLA4 seems to be a significant component of tolerance to tumor and in protection against immune mediated enterocolitis and these phenomena are significantly associated in cancer patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|